Drug Trial Radar · NCT06059547
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Sep 6, 2023
Primary completion
Oct 16, 2025
Study completion Jun 5, 2026
Sponsor
- Lead sponsor
- CatalYm GmbHIndustry
- Sponsor type
- Industry
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, stratified and single-blinded Phase 2 trial of neoadjuvant immunotherapy in combination with the anti-GDF15 antibody visugromab (CTL-002) for the treatment of participants with MIBC set to undergo radical Cystectomy (RC)/Re-TURBT who cannot receive or refuse to receive cisplatin-based chemotherapy.
Conditions
- Bladder Cancer
- Adult Solid Tumor
Interventions
NivolumabDrug
Biological, monoclonal antibody
Visugromab (CTL-002)Drug
Biological, monoclonal antibody
PlaceboDrug
Placebo (NaCl) for Visugromab (CTL-002)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological complete response rateTime frame: min. 4 months
- Radiological response rate according RECISTTime frame: min. 4 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
IRCCS Ospedale San Raffaele Hospital Vita-Salute San Raffaele University
Milan, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Oncologia Medica
Roma, Italy
A.O.U. Città della Salute e della Scienza di Torino
Torino, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.